3 results
"The primary objective of this study is to compare the clinical therapeutic effects of intravenous DP-b99 at adose of 1.0 mg/kg initiated within nine hours of stroke onset and administered daily over 2 hours for 4consecutive days versus placebo…
The primary objective of this study is to demonstrate the efficacy of the combination therapy of aliskiren (150 mg and 300 mg) and HCTZ 25 mg in hypertensive patients who do not show sufficient blood pressure response to a 4-week treatment of HCTZ…
Primary objectives:•To determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RPTD) of ABBV-155 administered as monotherapy (Part 1a)•To determine MTD and RPTD of ABBV-155 administered in combination with paclitaxel or docetaxel (…